IMMUNOVANT, INC. Effective Income Tax Rate Reconciliation Cross Border Tax Effect Amount
IMMUNOVANT, INC. (IMVT) reported Effective Income Tax Rate Reconciliation Cross Border Tax Effect Amount of -$64.51 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount · last filed 2026-05-20
- IMMUNOVANT, INC. effective income tax rate reconciliation cross border tax effect amount for fiscal 2026 was -$64.51M.
| Period end | Effective Income Tax Rate Reconciliation Cross Border Tax Effect Amount 12 month |
|---|---|
| 2026-03-31 | -$64.51M 10-K · filed 2026-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |